Recombinant Human Siglec-15 Fc Chimera Protein, CF

Recombinant Human Siglec-15 Fc Chimera (Catalog # 9227-SL) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect is 1-10 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Siglec-15 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1-10 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Siglec-15 protein
  

  Human Siglec-15 (Phe20-Thr263) Accession # Q6ZMC9	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6ZMC9
• N-terminal Sequence: Phe20
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity2
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 53-64 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS, NaCl, CHAPS and Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 200 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Siglec-15 Fc Chimera Protein, CF

• CD33 antigen-like 3SIGLEC-15
• CD33 molecule-like 3
• CD33L3
• HsT1361
• sialic acid binding Ig-like lectin 15
• sialic acid-binding Ig-like lectin 15
• Siglec15
• Siglec-15

Background

Siglec-15 is a transmembrane glycoprotein in the Siglec family of sialic acid-binding immune regulatory molecules (1). Mature human Siglec-15 consists of a 244 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain (2). Within the ECD, human Siglec-15 shares 85% aa sequence identity with mouse and rat Siglec-15. Alternative splicing generates an additional isoform that lacks the signal peptide and first Ig-like domain. Siglec-15 associates with the signaling molecules DAP12 and DAP10 (2-5). It is expressed on osteoclasts, macrophages, and dendritic cells (2-6) and binds to the sialyl-Tn antigen (2, 3, 6). This interaction induces the production of TGF-beta by tumor-associated macrophages (3). Siglec-15 function is important for osteoclast formation and TRANCE/RANK Ligand signaling in osteoclasts (4-6).

1. Humphrey, M.B. and M.C. Nakamura (2015) Clin. Rev. Allergy Immunol. PMID 26573914.
2. Angata, T. et al. (2007) Glycobiology 17:838.
3. Takamiya, R. et al. (2013) Glycobiology 23:178.
4. Kameda, Y. et al. (2013) J. Bone Miner. Res. 28:2463.
5. Stuible, M. et al. (2014) J. Biol. Chem. 289:6498.
6. Ishida-Kitagawa, N. et al. (2012) J. Biol. Chem. 287:17493.

Publications for Siglec-15 (9227-SL)(1)

Publication using 9227-SL

• Lee, BS;Cook, A;Sur, S;Dobbyn, L;Popoli, M;Khalili, S;Zhou, S;Bettegowda, C;Papadopoulos, N;Gabrielson, K;Buckhaults, P;Vogelstein, B;Kinzler, KW;Wyhs, N; NXPE1 alters the sialoglycome by acetylating sialic acids in the human colon Nature communications 2025-05-27 [PMID: 40425538] (Immunohistochemistry, Human)

Bioinformatics

• Uniprot:
  • Q6ZMC9()